Remove Coronary Artery Disease Remove Ischemia Remove Technology
article thumbnail

GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease

DAIC

Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.

article thumbnail

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

DAIC

It further reported that these results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease. “We He is the author of over 150 articles, book chapters, abstracts and other publications on advanced imaging technologies. James Min, M.D.

article thumbnail

GE Healthcare Launches New Cardiac PET tracer

DAIC

In 2024, the FDA approved Flyrcado for patients with known or suspected coronary artery disease (CAD), delivering higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) i myocardial perfusion imaging (MPI), the predominant procedure used in nuclear cardiology today. 2023 Oct, 82 (16) 15981610.

article thumbnail

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

DAIC

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Journal of Vascular Surgery, Mar.

article thumbnail

Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

DAIC

milla1cf Thu, 03/28/2024 - 07:00 March 28, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging on March 13, 2024. J Am Coll Cardiol. 2024.01.007.

Ischemia 110
article thumbnail

Elixir Medical Receives FDA Breakthrough Device Designation for DynamX BTK System for Below-The-Knee Arterial Disease

DAIC

Food and Drug Administration (FDA) for its DynamX BTK System, a novel, adaptive implant for use in the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients with chronic limb-threatening ischemia (CLTI). Peripheral arterial disease ( PAD ) affects more than 200 million people worldwide. J Vasc Surg.

article thumbnail

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

DAIC

The Freesolve BTK RMS is designed for individuals suffering from chronic limb-threatening ischemia (CLTI). CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. 2,3 It has shown 99.6%